<--GAT-->

Video-assisted Thoracoscopic Lobectomy Improves NSCLC Survival

by U.S. Medicine

November 9, 2017

HOUSTON—Should stereotactic body radiotherapy remain the standard treatment for medically inoperable early-Stage non-small cell lung cancer?

A study in the Journal of Thoracic and Cardiovascular Surgery supports the technique, which produces outcomes comparable to those of surgical resection in operable patients, but suggests the consideration of other options.1

Michael E. DeBakey VAMC-led researchers compared the outcomes of stereotactic body radiotherapy and video-assisted thoracoscopic lobectomy in veterans with early non-small cell lung cancer (NSCLC).

For the study, the team retrospectively reviewed data from 183 patients, almost all men, with clinical Stage I non-small cell lung cancer from 2009 to 2014. While 56 of them underwent stereotactic body radiotherapy, another 127 had video-assisted thoracoscopic lobectomy. Overall, patients who received stereotactic body radiotherapy were older than the patients who received video-assisted thoracoscopic lobectomy—median age, 79.5 vs. 64—and had more comorbidities.

Tumor control and overall, recurrence-free, and lung-cancer-specific survival were the primary endpoints.

Results indicated that, in the 37 propensity-matched pairs, the three-year actuarial tumor control rate was 54.3% after stereotactic body radiotherapy and 90.6% after video-assisted thoracoscopic lobectomy. Actuarial lung cancer-specific three-year survival was calculated to be 78.1% for stereotactic body radiotherapy vs. 93.6% for video-assisted thoracoscopic lobectomy.

Average survival rates also differed. Patients receiving stereotactic body radiotherapy had one-year survival rates of 89.2%, as well as three-year overall survival of 52.0% and three-year recurrence-free survival rate of 38.5%.

In comparison, the average one-year survival rate after video-assisted thoracoscopic lobectomy was 94.6%, and 85.7 and 82.8% for three-year overall and three-year recurrence-free survival, respectively.

“In multivariable analysis, stereotactic body radiotherapy independently predicted recurrence and poorer survival,” the study authors wrote.

The researchers noted that, for veteran patients with early-Stage non-small cell lung cancer, “video-assisted thoracoscopic lobectomy resulted in better disease control and survival than stereotactic body radiotherapy. Although prior reports suggest that stereotactic body radiotherapy is a suitable alternative to surgery in early-Stage lung cancer, a prospective randomized trial is needed. Nevertheless, stereotactic body radiotherapy remains a suitable option for medically inoperable patients.”

1 Cornwell LD, Echeverria AE, Samuelian J, Mayor J, et. cal.  Video-assisted thoracoscopic lobectomy is associated with greater recurrence-free survival than  stereotactic body radiotherapy for clinical Stage I lung cancer. J Thorac Cardiovasc Surg. 2017 Aug 16. pii: S0022-5223(17)31718-X. doi: 10.1016/j.jtcvs.2017.07.065. [Epub ahead of print] PubMed PMID: 28888379.

 


Comments are closed here.


Related Articles

Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

Veterans Study Calls for Better Guidance on Lung Cancer Treatment

With increased imaging now detecting lung cancer nodules in sicker patients, a new report suggested that guidelines should be more directive in how to maximize benefit and minimize harm, while taking into account comorbidities and life expectancy.


U.S. Medicine Recommends


More From oncology

Oncology

Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

Oncology

Veterans Study Calls for Better Guidance on Lung Cancer Treatment

With increased imaging now detecting lung cancer nodules in sicker patients, a new report suggested that guidelines should be more directive in how to maximize benefit and minimize harm, while taking into account comorbidities and life expectancy.

Oncology

VA/National Cancer Institute Partnership Increases Veteran Access to Trials

Thanks to a new partnership between the National Cancer Institute and the VA, veterans with cancer will now have greater access to potentially lifesaving clinical trials.

Oncology

VA Continues Hepatocellular Screening, but Study Questions the Value

Although a recent study determined that screening veterans with cirrhosis for hepatocellular carcinoma did not reduce the risk of death associated with liver cancer, the VA has no plans to change its screening practices.

Oncology

Testosterone Therapy Not Linked to Aggressive Prostate Cancer in Veterans

Clinicians prescribing supplemental testosterone in men with low levels always have a nagging concern about the possible link between increasing hormone levels and prostate cancer.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up